Gapping up
In reaction to earnings/guidance:
- STNE +19.9%, ROST +16.3%, CLFD +15%, FL +14.4%, PANW +9.8%, GPS +8.5%, TWST +8.5%, ATKR +5.5%, KEYS +5%, JD +4.7%, AMAT +4.1%, BKE +2.1%, GLOB +1.9%, POST +1.6%, UGI +1%
Other news:
- ISEE +23.7% (FDA grants breakthrough therapy designation)
- APLS +20.2% (FDA has accepted Apellis' unsolicited major amendment to the New Drug Application for intravitreal pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration)
- MGNX +8.1% (earns $60 mln milestone payment with FDA approval of Teplizumab)
- LPRO +6.9% (authorizes $75 mln repurchase program)
- EVH +6.4% (to acquire NIA from Centene)
- DOCN +4.2% (appoints new CFO)
- GOOS +3.3% (launches share repurchase program)
- ACMR +3.1% (enters the track market with new tool)
- ROG +3% (current CEO to retire appoints new CEO)
- AMD +2.5% (resolves patent litigations with ADI)
- RBT +2.4% (committed to a reduction in force plan to reduce spending and preserve cash)
- DDS +2.3% (declares special dividend)
- CSIQ +1.2% (Japan flagship mega-project reaches commercial operation)
- ORMP +1.1% (signs contract with MEDICOX to distribute oral insulin in South Korea)
Analyst comments:
- ABBV +0.6% (initiated with an Outperform at Credit Suisse)